

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI. Summary of all clinical reports of anti-PD-1 induced cutaneous lupus erythematosus (CLE) described in the literature

Autors, year, reference	Sex	Age	ICI	Onset of CLE after ICI-initiation (cycles, weeks or months)	Autoantibodies	Form of CLE	Localization of lesions	Treatment of CLE	Response to CLE treatment	Procedure regarding ICI	Underlying malignancy
Our report	F	23	P	2 cycles	ANA+ (1:640)	SCLE	Face, head, neck, and chest	Systemic steroids TCS HCQ	Resolution after ICI withdrawal despite discontinuation of CLE treatment	W	IDBC
Kosche et al., 2019 (7)	F	75	N	2 cycles	ANA+ (1:160) anti-Ro/SS-A+	SCLE	back, abdomen, arms, and legs	Systemic steroids TCS HCQ	Resolved within a week, recurred after switch to P, controlled with quinacrine	R	HGSOC
Shao et al., 2017 (8)	M	54	P	28 weeks	N/R	Lupus-like cutaneous reaction	back, chest, lateral arms, thighs, and abdomen	No medication	Resolved without CLE therapy	W	MM
Zitouni et al., 2019 (9)	F	72	N	13 cycles	ANA+ (1:640) anti-Ro/SS-A+ anti-La/SS-B+	SCLE	back and arms	HCQ	Resolved with residual scarring	W	MM
Zitouni et al., 2019 (9)	M	43	N	2 cycles	ANA (1:320) anti-SSA+ (>600 IU/ml)	SCLE	hands, arms, and chest, and then	Systemic steroids TCS HCQ	Resolved with residual scarring	W	NSCLC

							progression to the rest of the body				
Liu et al., 2018 (10)	F	58	N	20 weeks	Anti-Ro52+ Anti-Ro60+ Anti-cardiolipin antibodies+	SCLE	back and chest	Systemic steroids TCS HCQ	Controlled with HCQ and systemic steroids	R	NSCLC
Bui et al., 2021 (11)	F	54	N	80 weeks	ANA+ (>1:5120) anti-Ro/SS-A+ anti-La/SS-B+	SCLE	N/R	TCS HCQ	Resolved within a month	Continued throughout	SCLC
Bui et al., 2021 (11)	M	65	P	12 months	ANA+ (1:320) anti-Ro/SS-A+	SCLE	trunk and extremities	TCS HCQ	Improved after 2 months	N/R	SCLC
Bui et al., 2021 (11)	M	60	N	2 weeks	ANA+ (1:320) anti-Ro/SS-A+	SCLE	trunk and extremities	TCS	Improved after 2 months	Continued throughout	MM
Marano et al., 2019 (12)	M	60	N	2 cycles	ANA+ anti-Ro/SS-A+	SCLE	extensor arms and back, and the dorsal hands	Systemic steroids TCS HCQ	Resolved	R	SCLC
Marano et al., 2019 (12)	F	60	P	3 cycles	ANA+ (1:2560) anti-Ro/SS-A+ anti-La/SS-B+ anti-histone+	SCLE	face, upper back and chest, arms, forearms, and interphalangeal areas on the dorsal hands	Systemic steroids TCS	Resolved after 6 months of treatment	W	NSCLC

Blakeaway et al., 2019 (13)	F	79	P	3 cycles	ANA-	SCLE	face, arms, chest, and legs	TCS	Improved rapidly	R	MM
Blakeaway et al., 2019 (13)	M	75	P	9 cycles	ANA-	SCLE	chest, arms, and legs	TCS	Good response	R	MM
Blakeaway et al., 2019 (13)	F	55	P	3 cycles	anti-La/SS-B+ Anti-Sm/RNP+	DLE	hands, face, and scalp	Systemic steroids	N/A	N/R	MM
Andersson et al., 2021 (14)	F	66	P	29 cycles	ANA+ anti-Ro/SS-A+ anti-La/SS-B+	SCLE	Chest, back, extremities, lips and genital mucosa	Systemic steroids TCS HCQ	Resolved	W	NSCLC
Gambichler et al., 2021 (15)	M	52	P	2 cycles	anti-Ro60+	SCLE	trunk and extremities	Systemic steroids HCQ	N/A	W	NSCLC
Ogawa-Momohara et al., 2020 (16)	M	80	P	5 cycles	anti-Ro52+ anti-Ro60+	SCLE	trunk	Systemic steroids	Regression of erythema	N/R	MM
Fietz et al., 2023 (17)	F	64	C	5 weeks	anti-Ro52+	SCLE	V-area of the upper trunk and neck, forearms, dorsal hands,	Systemic steroids TCS	Resolved gradually	W	SCC

							lower legs, and dorsal feet				
Diago et al., 2021 (18)	F	66	N	6 cycles	ANA+(1:320) Anti-SSA/Ro60+	SCLE	upper trunk, back, arms, and cheeks	Systemic steroids	Resolved	R	LUAC
Diago et al., 2021 (18)	M	75	N	5 cycles	ANA+(1:320) Anti-SSA/Ro60+	SCLE	back, legs, arms, dorsal aspect of the hands, and cheeks	Systemic steroids	Resolved, then recurred	W	SCLC
Manjunath et al., 2022 (19)	M	61	N	84 weeks	ANA+ (1:80)	DLE	ears, posterior neck, forearms, and dorsal hands	TCS HCQ	Improved by 80%	R	HCC
Khorasanchi et al., 2024 (20)	M	75	N	1 cycle	ANA+ (1:160)	SCLE	dorsal forearms, upper arms, upper chest, and upper back	Systemic steroids TCS HCQ	Improved	W	GEJA

ICI: immune checkpoint inhibitors; N: nivolumab; P: pembrolizumab; C: cemiplimab; W: withdrawn; R: restarted; N/R: not reported; TCS: topical corticosteroids; HCC: hepatocellular carcinoma; HGSOc: high-grade serous ovarian cancer; IDBC: invasive ductal breast carcinoma; LUAC: lung adenocarcinoma; MM: malignant melanoma; NSCLC: non-small cell lung cancer; SCC: squamous cell carcinoma; SCLC: small cell lung cancer; GEJA: gastroesophageal junction adenocarcinoma.